Villalona-Calero, Miguel <br/><br/>
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jan 2007 
 - 23-33 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s00280-006-0249-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Area Under Curve<br/>Camptothecin--administration & dosage<br/>Celecoxib<br/>Chemotherapy, Adjuvant<br/>Chromatography, High Pressure Liquid<br/>Cyclooxygenase 2 Inhibitors--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Female<br/>Fibroblast Growth Factor 2--metabolism<br/>Follow-Up Studies<br/>Humans<br/>Irinotecan<br/>Male<br/>Middle Aged<br/>NF-kappa B--antagonists & inhibitors<br/>Neoplasms--drug therapy<br/>Pyrazoles--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Thalidomide--administration & dosage<br/>Tumor Necrosis Factor-alpha--metabolism